Table 2 Multivariate analysis of AIFM3 expression and clinical pathology factors
From: Clinical implications of a novel prognostic factor AIFM3 in breast cancer patients
Factors | Number (%) | AIFM3 expression | P | Adjusted OR (95 CI) | |
|---|---|---|---|---|---|
High (%) | Low (%) | ||||
Tumor size | |||||
≥ 3 cm | 87(57.6) | 62(71.3) | 25(28.7) | 0.223 | 0.494(0.159–1.537) |
< 3 cm | 64(42.4) | 33(51.6) | 31(48.4) | Reference | |
LN Metastases | |||||
negative | 86(57.0) | 44(51.2) | 42(48.8) | Reference | |
positive | 65(43.0) | 51(78.5) | 14(21.5) | 0.015 | 4.016(1.304–12.370) |
Molecular typing | |||||
Luminal A | 60(39.7) | 41(68.3) | 19(31.7) | 0.119 | 2.740(0.772–9.729) |
Luminal B | 48(31.8) | 32(66.7) | 16(33.3) | 0.550 | 1.536(0.376–6.274) |
Her-2 | 19(12.6) | 13(68.4) | 6(31.6) | 0.064 | 3.720(0.925–14.958) |
TNBC | 24(15.9) | 9(37.5) | 15(62.5) | Reference | |
TNM staging | |||||
I | 38(25.2) | 14(36.8) | 24(63.2) | Reference | |
II | 75(49.6) | 50(50.0) | 25(50.0) | 0.009 | 3.585(1.380–9.312) |
III | 38(25.2) | 31(81.6) | 7(18.4) | 0.003 | 6.073(1.871–19.710) |